메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Fills Global Gap

CHENGDU, China, Sept. 11, 2025 -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achieved high-resolution, molecular-level visualization of "collagen fiber bundles" under near-physiological and ultra-low temperature conditions using Cryo-Electron Microscopy (Cryo-EM). This achievement fills an international gap in the structural understanding of collagen fiber self-assembly
- 김갑성 기자
- 2025-09-11 21:27
Lunit Awarded Major National Tender in France, Expanding Access to Breast AI in Public Hospitals

Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that its breast imaging AI solutions have been selected under a national framework agreement led by UniHA, the largest central public procurement body for French hospitals. Under this four-year agreement, Lunit INSIGHT® MMG and DBT—Lunit's AI-powered software for mammography
- 김갑성 기자
- 2025-09-11 21:00
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Bridges International Gap

CHENGDU, China, Sept. 11, 2025 -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd., announced that its self-developed POGMENT triple-helix biomimetic collagen has, for the first time globally, achieved high-resolution molecular visualization of "collagen fiber bundles" using Cryo-Electron microscopy (Cryo-EM) under near-physiological and cryogenic conditions. This breakthrough fills the international knowledge gap in understanding collagen's self-assembly mechanism. The result was achieved through collaboration with the Cryo-EM platform te
- 김갑성 기자
- 2025-09-11 20:26
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC

SHANGHAI, Sept. 11, 2025 -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately $45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will support the advancement of YolTech's clinical programs and global strategic execution. Dr. Yuxuan Wu, Founder and CEO of YolTech, "This financing marks an important milestone as we continue advancing our pipeline toward transformative therapies. We are committed to turning cutting-edge gene-editing scien
- 김갑성 기자
- 2025-09-11 20:05
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy

SYDNEY, Sept. 11, 2025 -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-positive metastatic breast cancer (mBC) patients were profiled to evaluate the effect of paxalisib, Kazia's investigational PI3K–mTOR inhibitor, on metastatic burden. Paxalisib monotherapy demonstrated a statistically significant reduction in single circulating tumor cells and achieved a complete (100%) dis
- 김갑성 기자
- 2025-09-11 20:00
Lundbeck showcases new clinical migraine data, including long-term preventive effectiveness of Vyepti® (eptinezumab) in patients severely impacted by migraine

[ 메디채널 김갑성 기자 ] Lundbeck demonstrates leadership and unwavering commitment to advancing migraine management and supporting patient outcomes with six presentations at the 2025 International Headache Congress (IHC), including three oral presentations on eptinezumab (Vypeti®) and Lu AG09222 (anti-PACAP mAb) New data from the open-label extension of the RESOLUTION trial and the primary results of the SUNSET extension trial will be presented for the first time at IHC1,2 Patients treated with eptinezumab experienced sustained reductions in migraine symptom and burden, including long-term r
- 김갑성 기자
- 2025-09-11 14:56
HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025

SYDNEY, Sept. 11, 2025 -- HaemaLogiX Ltd, a clinical stage Australian biotech, developing novel immunotherapies for patients with blood cancers and B-cell diseases, was honoured to be awarded the "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT Excellence Awards 2025, held in Singapore last night. The award recognises companies demonstrating outstanding innovation, scientific excellence, and translational potential in the rapidly evolving CAR T therapy sector. This accolade highlights HaemaLogiX's role as a leader in advancing CAR T-cell therapies that
- 김갑성 기자
- 2025-09-11 11:52
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"

[ 메디채널 김갑성 기자 ] 50-Person Team Demonstrates Taiwan's Biotech Strength HSINCHU, Sept. 11, 2025 -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was awarded the "Best Fill-Finish" at the 2025 Asia-Pacific Biologics CDMO Excellence Awards held in Singapore on September 10. This honor recognizes Amaran Biotech's leading capabilities in aseptic fill-finish processes and marks an important step for Taiwan's biotech industry on the international stage. The Asia-Pacific Biologics CDMO Excellence Awards, organized by the renowne
- 김갑성 기자
- 2025-09-11 10:00
SynbioTech's TWK10 Approved to Boost Muscle Strength, The Probiotic Pioneer Marches Toward Southeast Asia Market

BANGKOK, Sept. 11, 2025 -- SynbioTech Inc., ranked among the world's top 20 probiotic suppliers, is the leader in functional probiotics for muscle and joint health, sports, women's wellness, and immune support. Its patented flagship probiotic, Lactiplantibacillus plantarum TWK10®, has earned multiple awards in Europe, the US and Japan, with clinical trials showing increased muscle mass and reduced body fat. In 2024, TWK10® was approved by the Thai government as an edible strain, making it a key focus in the Thai market. SynbioTech will showcase this and other flagship probiotics at Vi
- 김갑성 기자
- 2025-09-11 10:00
Fosun International Recognized among Fortune's 2025 "Most Admired Chinese Companies" List

HONG KONG, Sept. 11, 2025 -- On 9 September, Fortune China magazine released its 2025 list of "Most Admired Chinese Companies", in which Fosun International Limited ("Fosun International" or the "Company") (HKEX stock code: 00656) was included in the Industry Star List. This highlights Fosun's outstanding performance and industry leadership in environmental, social, and corporate governance (ESG), employee responsibility, and value creation for stakeholders. Fortune China pointed out that the list evaluates company performance across multiple dimensions. C
- 황정호 기자
- 2025-09-11 09:00

이전

61 62 63 64 65 66 67 68 69 70

많이 본 기사

최근기사

2025-11-05_WED

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 05일 07시 20분